Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315730 | 1.00 | ALOX5AP (0.47) | ALOX5APFEN1F2RL3GPR119CHEK2 | |
| SCHEMBL13362068 | 0.86 | PARP15 (0.46) | ALOX5APPARP15PARP10HSD11B1CHRNB4 | |
| SCHEMBL3317820 | 0.86 | PARP15 (0.46) | PARP15PARP10HSD11B1CHRNB4CHRNA3 | |
| SCHEMBL3311674 | 0.86 | PARP15 (0.46) | PARP15PARP10HSD11B1CHRNB4CHRNA3 | |
| SCHEMBL6535548 | 0.85 | GPR119 (0.49) | ALOX5APFEN1F2RL3GPR119CHEK2 | |
| SCHEMBL6535308 | 0.85 | GPR119 (0.49) | ALOX5APFEN1F2RL3GPR119CHEK2 | |
| SCHEMBL3319038 | 0.84 | ALOX5AP (0.46) | ALOX5APFEN1F2RL3GPR119CHRNB4 | |
| SCHEMBL3319033 | 0.84 | ALOX5AP (0.46) | ALOX5APFEN1F2RL3GPR119CHRNB4 | |
| SCHEMBL6195438 | 0.84 | ALOX5AP (0.52) | ALOX5APFEN1GPR119CHEK2 | |
| SCHEMBL6182367 | 0.84 | ALOX5AP (0.52) | ALOX5APFEN1GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | ALOX5AP 1831/4885FEN1 1530/4885F2RL3 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.